Faculty profile

Anne-Marie Mes-Masson

ResearcherMedicineUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses may be missing. Find their university profile.

Anne-Marie Mes-Masson

Researcher

Medicine

Health Sciences

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
34 publications in the last five years, latest in 2026.
Senior (last) author on 3 recent papers, a sign of leading a research group.
Principal investigator on 5 research grants (5 CIHR), most recently in 2023.
Supervised 1 trainee who won CIHR awards, most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

151

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Medicinal Chemistry Ovarian Cancer Therapeutics Estrogen Deprivation Menopause New Therapeutic Strategies Senescence Women'S Health

Latest papers

The Genetic and Molecular Analyses of Rare Candidate Germline BRIP1/FANCJ Variants Implicated in Hereditary Breast and Ovarian Cancers.
International journal of molecular sciences · 2026
Transforming Biospecimen Management: A Roadmap for Integrated Sample Traceability in the Era of Global Research.
Biopreservation and biobanking · 2026
Co-occurring rare germline DNA repair gene variants in BRCA1/BRCA2 implicated hereditary breast cancer families.
NPJ breast cancer · 2026

All 151 publications

Latest funding

Unveiling the Role of Cellular Aging in Postmenopausal Syndrome: Rationale for Senolytic-Based Strategies to Enhance Women's Health
CIHR · 2023 · Nominated PI
$108,000
Senolytic therapy for Menopause Induced Senescent Cells, the pathological mediators of estrogen deprivation.
CIHR · 2023 · Supervisor
$135,000
Innovation of Proprietary Liquid Biopsy Assays for Diagnosis of Early Stage Ovarian Cancer
CIHR · 2021 · Co-investigator
$650,251

All 11 grants and awards

From the 150 most recent of 151 publications.

The Genetic and Molecular Analyses of Rare Candidate Germline BRIP1/FANCJ Variants Implicated in Hereditary Breast and Ovarian Cancers.

Alenezi WM, Milano L, Fierheller CT, Serruya C, Revil T, Oros KK, Bruce JP, Spiegelman D, Pugh T, Mes-Masson AM, Provencher D, Foulkes WD, El Haffaf Z, Rouleau G, Bouchard L, Greenwood CMT, Ragoussis J, Masson JY, Tonin PN

International journal of molecular sciences2026

DOI: 10.3390/ijms27021037 PMID: 41596682

Transforming Biospecimen Management: A Roadmap for Integrated Sample Traceability in the Era of Global Research.

Sion SI, Nguyen-Phan T, Fortin M, Mes-Masson AM, Zhang K

Biopreservation and biobanking2026

DOI: 10.1177/19475535251366364 PMID: 40793957

Co-occurring rare germline DNA repair gene variants in BRCA1/BRCA2 implicated hereditary breast cancer families.

Alenezi WM, Recio N, Fierheller CT, Serruya C, Revil T, Mes-Masson AM, Provencher D, Greenwood CMT, Ragoussis J, Tonin PN

NPJ breast cancer2026

DOI: 10.1038/s41523-026-00956-7 PMID: 42086605

Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.

Gambaro K, Rachedi K, Basik M, Batist G, Saad F, Hassan S, Mes-Masson AM, Boudreau D, Vincent F, St-Hilaire E, Mackay H, Abdelsalam M, Yip SM, Hanel R, Shokar S, Senhaji Mouhri Z, Badin M, Klein-Panneton K, Awan AA, Marques M

Advances in therapy2026

DOI: 10.1007/s12325-026-03545-z PMID: 41806276

ATM c.7374_7375insAlu is a French-Canadian founder pathogenic variant associated with predisposition to pancreatic and breast cancer.

Wang Y, Domecq C, Cuggia A, Mejia-Garcia A, Romero JM, Hamel N, Lapointe R, Provencher D, Mes-Masson AM, Tonin PN, Gravel S, Zogopoulos G, Foulkes WD

Journal of medical genetics2026

DOI: 10.1136/jmg-2025-111441 PMID: 41916721

SMARCA4 regulates the NK-mediated killing of senescent cells.

Reen V, D'Ambrosio M, Søgaard PP, Tyson K, Leeke BJ, Clément I, Dye ICA, Pombo J, Kuba A, Lan Y, Burr J, Bomann IC, Kalyva M, Birch J, Khadayate S, Young G, Provencher D, Mes-Masson AM, Vernia S, McGranahan N, Brady HJM, Rodier F, Nativio R, Percharde M, McNeish IA, Gil J

Science advances2025

DOI: 10.1126/sciadv.adn2811 PMID: 39813356

PMS2 c.2117del (p.Lys706Serfs*19) is the Most Frequent Cancer-Associated Founder Pathogenic Variant in the French-Canadian Population of Quebec, Canada.

Chong AL, Mejia-Garcia A, Behl S, El Haffaf Z, Chénier S, Maranda B, Désilets V, Lévesque S, Castonguay L, Mes-Masson AM, Giroux S, Rousseau F, Hamel N, Chong G, Gravel S, Foulkes WD

Clinical genetics2025

DOI: 10.1111/cge.14784 PMID: 40546006

Mass fabrication of PDMS microfluidic devices by injection molding and applications in sensitive 3D spheroid and explant culture.

Filion R, St-Georges-Robillard A, Chaudoir H, Ritch S, Ndongo M, Chua XY, Laurent E, Mes-Masson AM, Ajji A, Gervais T

Scientific reports2025

DOI: 10.1038/s41598-025-16863-z PMID: 41006408

The journey from bench to bedside-it takes a science village.

Mes-Masson AM

Biochemistry and cell biology = Biochimie et biologie cellulaire2024First author

DOI: 10.1139/bcb-2024-0075 PMID: 38640502

Author Correction: Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.

Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, Sauriol SA, Communal L, Leclerc-Desaulniers K, Carmona E, Provencher D, Mes-Masson AM, Rodier F

Nature communications2024

DOI: 10.1038/s41467-024-48270-9 PMID: 38740764

Something wrong or missing on this profile? Suggest a correction

Anne-Marie Mes-Masson

Research

Latest papers

Latest funding

The Genetic and Molecular Analyses of Rare Candidate Germline BRIP1/FANCJ Variants Implicated in Hereditary Breast and Ovarian Cancers.

Transforming Biospecimen Management: A Roadmap for Integrated Sample Traceability in the Era of Global Research.

Co-occurring rare germline DNA repair gene variants in BRCA1/BRCA2 implicated hereditary breast cancer families.

Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.

ATM c.7374_7375insAlu is a French-Canadian founder pathogenic variant associated with predisposition to pancreatic and breast cancer.

SMARCA4 regulates the NK-mediated killing of senescent cells.

PMS2 c.2117del (p.Lys706Serfs*19) is the Most Frequent Cancer-Associated Founder Pathogenic Variant in the French-Canadian Population of Quebec, Canada.

Mass fabrication of PDMS microfluidic devices by injection molding and applications in sensitive 3D spheroid and explant culture.

The journey from bench to bedside-it takes a science village.

Author Correction: Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.

Frequent collaborators

Dominique Trudel

Dominique Trudel

Alan So

Francis Rodier

Antonio Finelli

Jean-Yves Masson

Luigi Bouchard

Robert Rottapel

Luigi Bouchard

Stephanie Lheureux

Guy Rouleau

Simon Gravel

Samuel Aparicio

John Stagg

Alexandre Orthwein

Marie-Claude Bourgeois-Daigneault

Réjean Lapointe

Ali Bashashati

Trevor Pugh

Carmen Loiselle

Jacek Majewski

Barbara Vanderhyden

Caroline Boudoux

Benjamin Haibe-Kains

Vincent Mooser

Yemin Wang

Amit Oza

Adi Steif

Yann Joly

Anita Koushik

Daniel Lamarre

Eva Tomiak

Martin Gleave

Philippe Gros

Nathalie Grandvaux

Martin Hirst

Shabbir Alibhai

Mathieu Blanchette

Catherine Laprise

Gustavo Turecki